Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis

Annals of Neurology

Volumn 74, Issue 2, 2013, Pages 180-187

  Ciura, Sorana ^a   Lattante, Serena ^a   Le Ber, Isabelle ^a,b   Latouche, Morwena ^a   Tostivint, Hervé ^c   Brice, Alexis ^a,b   Kabashi, Edor ^a  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; MORPHOLINO OLIGONUCLEOTIDE;

ALTERNATIVE RNA SPLICING; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ESCAPE BEHAVIOR; FRONTOTEMPORAL DEMENTIA; GENE OVEREXPRESSION; GENETIC MODEL; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LOCOMOTION; LYMPHOBLAST; MOTOR DYSFUNCTION; NERVE FIBER; NERVE PROJECTION; NERVOUS SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; SWIMMING; TACTILE STIMULATION; TRANSLATION INITIATION; ZEBRA FISH;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; LYMPHOCYTES; MOTOR ACTIVITY; PROTEINS; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84881531855     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23946     Document Type: Article

References (31)

1. Pasinelli P, Brown RH,. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7: 710-723.
2. Harvey RJ, Skelton-Robinson M, Rossor MN,. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 2003; 74: 1206-1209.
3. Lomen-Hoerth C, Anderson T, Miller B,. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59: 1077-1079.
4. Burrell JR, Kiernan MC, Vucic S, Hodges JR,. Motor neuron dysfunction in frontotemporal dementia. Brain 2011; 134: 2582-2594.
5. Ringholz GM, Appel SH, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65: 586-590.
6. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133.
7. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256.
8. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268.
9. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11: 323-330.
10. Le Ber I, Camuzat A, Guillot-Noel L, et al. C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis 2013; 34: 485-499.
11. Millecamps S, Boillée S, Le Ber I, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 2012; 49: 258-263.
12. Cooper-Knock J, Hewitt C, Highley JR, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012; 135: 751-764.
13. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135: 693-708.
14. Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012; 11: 54-65.
15. Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013; 77: 639-646.
16. Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013; 339: 1335-1338.
17. Rademakers R, Neumann M, Mackenzie IR,. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012; 8: 423-434.
18. Taylor JP,. Neuroscience. RNA that gets RAN in neurodegeneration. Science 2013; 339: 1282-1283.
19. Thisse C, Thisse B,. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc 2008; 3: 59-69.
20. Kabashi E, Lin L, Tradewell ML, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 2010; 19: 671-683.
21. Kabashi E, Bercier V, Lissouba A, et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet 2011; 7: e1002214.
22. Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012; 18: 1418-1422.
23. Rutherford NJ, Heckman MG, Dejesus-Hernandez M, et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging 2012; 33: 2950.e5-e7.
24. Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 2013; 92: 345-353.
25. Mackenzie IR, Rademakers R, Neumann M,. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995-1007.
26. Lee EB, Lee VM, Trojanowski JQ,. Gains or losses: molecular mechanisms of TDP-43-mediated neurodegeneration. Nat Rev Neurosci 2011; 13: 38-50.
27. Pearson CE,. Repeat associated non-ATG translation initiation: one DNA, two transcripts, seven reading frames, potentially nine toxic entities! PLoS Genet 2011; 7: e1002018.
28. Vaccaro A, Patten SA, Ciura S, et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS One 2012; 7: e42117.
29. Kabashi E, Champagne N, Brustein E, Drapeau P,. In the swim of things: recent insights to neurogenetic disorders from zebrafish. Trends Genet 2010; 26: 373-381.
30. Armstrong GA, Drapeau P,. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. J Neurosci 2013; 33: 1741-1752.
31. McGown A, McDearmid JR, Panagiotaki N, et al. Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Ann Neurol 2013; 73: 246-258.